Literature DB >> 1147580

Pipemidic acid: absorption, distribution, and excretion.

M Shimizu, S Nakamura, Y Takase, N Kurobe.   

Abstract

Pipemidic acid was absorbed well by the oral route. Its peak levels in plasma ranged from 4 to 12 mug/ml at an oral dose of about 50 mg/kg in mice, rats, dogs, monkeys, and men. The protein binding of pipemidic acid was about 20% in dog plasma and about 30% in human serum. Pipemidic acid was distributed to most of the organs and tissues tested at the concentrations comparable to or higher than the plasma level. Its concentrations in bile and urine were much higher than the plasma level. About 25 to 88% of orally administered pipemidic acid was excreted into urine in a bacteriologically active form, the percentage depending on the animals and doses employed. The remainder was excreted into feces in men. The main active principle in vivo was unchanged pipemidic acid itself. The mean lethal dose of pipemidic acid after a single oral dose was more than 16,000 mg/kg in mice. No abnormalities were observed in mice orally receiving pipemidic acid once a day for 4 weeks at doses of 1,000, 2,000, and 4,000 mg/kg per day, and in rats orally receiving the drug once a day for 2 weeks at doses of 400 and 1,600 mg/kg per day.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1147580      PMCID: PMC429159          DOI: 10.1128/AAC.7.4.441

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  ABSORPTION, EXCRETION, AND METABOLISM OF A NEW ANTIBACTERIAL AGENT, NALIDIXIC ACID.

Authors:  E W MCCHESNEY; E J FROELICH; G Y LESHER; A V CRAIN; D ROSI
Journal:  Toxicol Appl Pharmacol       Date:  1964-05       Impact factor: 4.219

2.  Oxolinic acid metabolism by man.

Authors:  F J Dicarlo; M C Crw; M D Melgar; S Roemer; S M Ringel; L J Haynes; M Wilson
Journal:  Arch Int Pharmacodyn Ther       Date:  1968-08

3.  High-efficiency liquid-scintillation counting of 14C-labelled material in aqueous solution and determination of specific activity of labelled proteins.

Authors:  T C Hall; E C Cocking
Journal:  Biochem J       Date:  1965-09       Impact factor: 3.857

  3 in total
  10 in total

1.  Selective decontamination of the digestive tract by pipemidic acid.

Authors:  H L Muytjens; G L van Veldhuizen; G W Welling; J van der Ros-van de Repe; H B Boerema; D van der Waaij
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

2.  Determination of pipemidic acid in plasma by normal-phase high-pressure liquid chromatography.

Authors:  H Ito; M Inoue; M Morikawa; M Tsuboi; K Oka
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

3.  Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers.

Authors:  E Klinge; P T Männistö; R Mäntylä; J Mattila; U Hänninen
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

4.  Pharmacokinetic determination of relative potency of quinolone inhibition of caffeine disposition.

Authors:  G Barnett; J Segura; R de la Torre; M Carbó
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Pipemidic acid: its activities against various experimental infections.

Authors:  M Shimizu; Y Takdase; S Nakamura; H Katae; A Minami
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

6.  Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: in vitro properties.

Authors:  M Shimizu; Y Takase; S Nakamura; H Katae; A Minami
Journal:  Antimicrob Agents Chemother       Date:  1975-08       Impact factor: 5.191

7.  Comparative pharmacokinetic profiles of cinoxacin and pipemidic acid in humans.

Authors:  J M Brogard; F Comte; J Lavillaureix
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983 Jul-Sep       Impact factor: 2.441

8.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

9.  In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.

Authors:  S A Chartrand; R K Scribner; A H Weber; D F Welch; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

10.  New Pharmacokinetic and Microbiological Prediction Equations to Be Used as Models for the Search of Antibacterial Drugs.

Authors:  Jose I Bueso-Bordils; Gerardo M Antón-Fos; Antonio Falcó; Maria J Duart; Rafael Martín-Algarra; Pedro A Alemán-López
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.